Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account.
作者信息
Herlyn Meenhard, Villanueva Jessie
机构信息
Molecular & Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, USA.
出版信息
Pigment Cell Melanoma Res. 2023 Nov;36(6):583-587. doi: 10.1111/pcmr.13133. Epub 2023 Sep 19.
Abstract
摘要
相似文献
1
Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account.黑色素瘤治疗二十年研究历程——从“无药可用”到治愈：个人亲历
Pigment Cell Melanoma Res. 2023 Nov;36(6):583-587. doi: 10.1111/pcmr.13133. Epub 2023 Sep 19.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?B-Raf 抑制剂单药治疗转移性 B-Raf 突变型黑色素瘤的疗效：抑制热情？
J Oncol Pharm Pract. 2021 Jan;27(1):205-206. doi: 10.1177/1078155220975079. Epub 2020 Nov 26.
4
Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.三药联合疗法治疗黑色素瘤——BRAF/MEK 抑制剂联合抗 PD-(L)1 抗体。
Curr Oncol Rep. 2022 Aug;24(8):1071-1079. doi: 10.1007/s11912-022-01243-x. Epub 2022 Apr 2.
5
[Immunotherapy for BRAF mutant metastatic melanoma.].BRAF突变转移性黑色素瘤的免疫疗法。
Recenti Prog Med. 2020 Dec;111(12):48e-53e. doi: 10.1701/3509.34976.
6
The emergence of neoadjuvant immune- over BRAF therapy in melanoma.黑色素瘤中BRAF靶向新辅助免疫治疗的出现。
Cancer. 2024 Oct 15;130(20):3409-3411. doi: 10.1002/cncr.35490. Epub 2024 Jul 22.
7
The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.BRAF 靶向治疗联合免疫疗法在黑色素瘤中的潜力。
Expert Rev Anticancer Ther. 2020 Feb;20(2):131-136. doi: 10.1080/14737140.2020.1724097. Epub 2020 Feb 5.
8
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.BRAF突变和BRAF抑制对黑色素瘤免疫反应的影响。
Mol Cancer Ther. 2014 Dec;13(12):2769-83. doi: 10.1158/1535-7163.MCT-14-0290. Epub 2014 Nov 10.
9
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.BRAF V600 野生型皮肤黑色素瘤的治疗策略。
Am J Clin Dermatol. 2024 May;25(3):407-419. doi: 10.1007/s40257-023-00841-0. Epub 2024 Feb 8.
10
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.自然杀伤细胞对于 BRAF 抑制剂控制 BRAFV600E 突变转移性黑色素瘤的能力至关重要。
Cancer Res. 2014 Dec 15;74(24):7298-308. doi: 10.1158/0008-5472.CAN-14-1339. Epub 2014 Oct 28.
引用本文的文献
1
Advances in Pathogenesis and Treatment of Skin Cancer.皮肤癌发病机制与治疗的进展
Int J Mol Sci. 2025 Jan 31;26(3):1255. doi: 10.3390/ijms26031255.
本文引用的文献
1
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.黑色素瘤的十年检查点阻断免疫治疗：了解免疫敏感性和耐药性的分子基础。
Nat Immunol. 2022 May;23(5):660-670. doi: 10.1038/s41590-022-01141-1. Epub 2022 Mar 3.
2
Melanoma models for the next generation of therapies.下一代疗法的黑色素瘤模型。
Cancer Cell. 2021 May 10;39(5):610-631. doi: 10.1016/j.ccell.2021.01.011. Epub 2021 Feb 4.
3
Toward Minimal Residual Disease-Directed Therapy in Melanoma.迈向黑色素瘤的微小残留病灶导向治疗。
Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12.
4
Genetically engineered mouse models of melanoma.黑色素瘤的基因工程小鼠模型
Cancer. 2017 Jun 1;123(S11):2089-2103. doi: 10.1002/cncr.30684.
5
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.通过肿瘤基因组分析解析黑色素瘤中 RAF 抑制治疗抵抗。
J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.
6
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.黑色素瘤中 RAF 激酶开关介导的 BRAF 抑制剂获得性耐药可以通过共靶向 MEK 和 IGF-1R/PI3K 来克服。
Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023.
7
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.黑色素瘤通过 RTK 或 N-RAS 上调获得对 B-RAF(V600E)抑制的耐药性。
Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.
8
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.COT 通过激活 MAP 激酶通路驱动 RAF 抑制耐药。
Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.
9
Oncogenic Braf induces melanocyte senescence and melanoma in mice.致癌性Braf在小鼠中诱导黑素细胞衰老和黑色素瘤。
Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.
10
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.Braf（V600E）与PTEN缺失共同作用诱导转移性黑色素瘤。
Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12.
Zotero 插件